Common antidepressant may ease long COVID fatigue

A randomized clinical trial found that the antidepressant fluvoxamine significantly reduces long COVID-related fatigue, one of the condition's most persistent and debilitating symptoms, while the diabetes drug metformin showed no benefit. Patients taking fluvoxamine reported steadily improving fatigue and quality-of-life scores over 60 to 90 days, with fewer side effects than those on placebo. The findings are published in Annals of Internal Medicine.